Mesenchymal stem cells (MSCs) are adult stem cells found in various tissues including bone marrow, adipose (fat) tissue, and umbilical cord (Wharton's jelly). In research settings, they are studied for their ability to release bioactive molecules that may influence inflammation, support tissue repair, and modulate immune responses. The MSCs used in our partner laboratories are derived from donated umbilical cord tissue following strict ethical and regulatory guidelines (COFEPRIS oversight).

Current scientific literature indicates that MSCs primarily exert their effects through paracrine signaling – meaning they secrete growth factors, cytokines, and extracellular vesicles (exosomes) that communicate with nearby cells. These molecules can influence inflammation, cell survival, blood vessel formation, and tissue homeostasis. Unlike earlier theories, MSCs do not typically differentiate into target tissues in significant numbers; their therapeutic potential in research models is largely attributed to this paracrine activity rather than direct replacement of damaged cells.

In the United States, most MSC therapies are considered investigational and have not received FDA approval for general use. The FDA has approved only certain hematopoietic (blood‑forming) stem cell products for specific conditions. In Mexico, COFEPRIS (the federal health authority) regulates stem cell clinics and laboratories. Our partner facilities operate under COFEPRIS regulations and licensing. However, these treatments remain categorized as "investigational" or "experimental" by international standards. Patients should understand that MSC therapies are not FDA‑approved and that individual outcomes vary.

Ongoing clinical research is exploring MSCs for a wide range of conditions, including:

• Orthopedic: osteoarthritis, cartilage defects, tendon injuries
• Autoimmune/inflammatory: rheumatoid arthritis, Crohn's disease, lupus
• Neurological: Parkinson's disease, multiple sclerosis, spinal cord injury
• Pulmonary: COPD, pulmonary fibrosis, post-COVID respiratory complications
• Metabolic: type 2 diabetes, diabetic neuropathy

It is important to note that many of these applications are still in early to mid‑stage trials, and evidence for efficacy varies by condition. No guarantees of improvement can be made.

All physicians in our network are fully licensed medical doctors in Mexico, with credentials verifiable through Mexican health authorities. Our partner laboratories are licensed and regulated by COFEPRIS, the Mexican equivalent of the FDA, and follow Good Manufacturing Practices (GMP) for cell processing. We do not claim US-based accreditations (e.g., AABB, FACT) unless explicitly stated on a case‑by‑case basis. You may request documentation of licensing and certifications directly from our medical team.

Autologous MSCs are derived from the patient's own tissue (e.g., bone marrow or fat). They carry no risk of immune rejection but may have reduced potency in older or sicker individuals. Allogeneic MSCs come from a healthy donor (often umbilical cord tissue). They are considered "off‑the‑shelf" and are studied for their consistent quality and low immunogenicity (due to low expression of MHC class II molecules). Both types are used in research; allogeneic MSCs from umbilical cord are the primary focus of our educational resources because they are more standardized.

As with any medical procedure, there are potential risks. Published studies report that MSC infusions are generally well‑tolerated, but possible side effects include transient fever, headache, nausea, injection site reactions (for local injections), and, rarely, allergic reactions or infections. Theoretical risks such as ectopic tissue formation or tumorigenesis have not been observed in clinical trials to date but cannot be completely ruled out. A thorough medical evaluation is required before considering any treatment. Our physician network discusses all known risks during consultation.

Reported timelines vary widely depending on the condition, the route of administration, and individual patient factors. Some individuals report subjective improvements within weeks, while others may require several months. The paracrine effects of MSCs (anti‑inflammatory signaling, growth factor release) are thought to initiate a cascade that may take time to manifest clinically. There is no standardised timeline, and outcomes are not guaranteed. Our educational materials emphasize realistic expectations and the importance of concurrent rehabilitation and nutritional support.

All procedures coordinated through our network are performed in Guadalajara, Mexico, at licensed partner facilities. We do not offer remote or home‑based stem cell administration. Patients are required to travel to Guadalajara for a pre‑procedure medical evaluation, the treatment itself (typically intravenous infusion or local injection), and initial recovery observation. We assist with travel and accommodation information but do not directly book travel. Telemedicine consultations are available for preliminary eligibility discussions.

Yes, thousands of peer‑reviewed studies have investigated MSC biology. Preclinical models and early‑phase human trials support the paracrine, immunomodulatory, and anti‑inflammatory mechanisms described on this site. Major scientific journals (e.g., Stem Cells Translational Medicine, Cytotherapy) have published systematic reviews and meta‑analyses. However, much of the evidence remains preliminary, and large, randomized controlled trials are still needed for many indications. Our resources always distinguish between established mechanisms and still‑investigational clinical applications. Consult your physician for an evidence‑based discussion.